Today, we’re excited to welcome Sarah Teichmann to Gravity Encounters.

As Professor of Stem Cell Biology at the University of Cambridge and Vice President for Translational Research at GSK, Sarah has had a profound impact on single-cell genomics, immunology, and translational medicine.

Previously, she held positions at the MRC Laboratory of Molecular Biology, the European Bioinformatics Institute, and the Wellcome Sanger Institute, where she led large-scale single-cell projects that have transformed our understanding of human health and disease.

Sarah has co-founded Transition Bio and EnsoCell Therapeutics, applying single-cell and spatial genomics technologies, AI, and machine learning to drive novel therapeutic discovery. In addition, she is co-founder and co-leader of the international Human Cell Atlas consortium, which aims to create comprehensive reference maps of every human cell type.

Today, we’ll explore Sarah’s journey, from working on the fundamental principles of cell biology to leading global consortia and companies at the forefront of translational research.

Hosts: Emily James and Claudia Smith

In this episode, we’re delighted to welcome Professor Anne Ferguson-Smith. Anne is a globally recognised expert in mammalian genetics and epigenetics, and currently holds the Arthur Balfour Professorship of Genetics at Cambridge. Her research investigates how epigenetic mechanisms regulate genome function, with a focus on how genetic and environmental factors influence development, health, and disease. She is also the Executive Chair of the Biotechnology and Biological Sciences Research Council (BBSRC) and the former Pro-Vice-Chancellor for Research and International Partnerships at the University of Cambridge.

In this conversation, Anne shares insights into her journey into science, the vital role of epigenetics in understanding complex biological systems, and her leadership path in research and policy.

This episode was recorded a while ago, so some of the information may be out of date.

Hosts: Laura Ryan and Laura Lungu

Link to YouTube video: https://www.youtube.com/watch?v=hsNAyfQHSYE

In this episode, we’re delighted to welcome Alan Rigby to Gravity Encounters. With a career spanning academia, biotech, and drug discovery, Alan has made a significant impact on cancer research and immunotherapy. From his time as an Assistant Professor at Harvard to leading multiple innovative companies, he has been at the forefront of tumor biology, computational drug discovery, and antibody therapeutics. Now the CEO of Epitopea, Alan continues to drive breakthroughs in the field, shaping the future of cancer immunotherapies and vaccines.